This week in Barks & Bites: American pharmaceutical firm Johnson & Johnson announces $55 billion in U.S. factory investments to stay ahead of drug tariffs; the Court of Justice for the European Union reports a decrease in new IP cases in 2024 despite a 12% increase in overall litigation before the Court that year; the Federal Circuit issues precedential decisions confirming Hatch-Waxman litigation expenses as tax deductible, rejecting Abiomed’s bid to extend the doctrine of prosecution disclaimer, and confirming that the zone of natural expansion doctrine is purely defensive in trademark litigation; Mariah Carey wins summary judgment and a sanctions motion in a copyright case over “All I Want For Christmas is You”; the Patent Trial and Appeal Board issues an informative designation to a denial of inter partes review institution over inconsistent claim construction arguments; and the ITC says that Samsung Display did not prove a violation of Section 337 by active matrix OLED products imported into the U.S. by BOE Technology.
Recent Posts
- Understanding IP Matters: Celebrated MIT Engineer and Entrepreneur Develops Medical Devices to Treat Cancer and Other Diseases
- CAFC Finds IPR Petitioner Did Not Rely on AAPA as Basis for Obviousness Grounds in Affirming PTAB Invalidation
- Foreign Price Controls: A Risk to U.S. Medical Innovation and Patient Access
- Other Barks & Bites for Friday, July 11: EGC Affirms Annulment of Rubik’s Cube Marks; Sysco Trade Secret Case Dismissal Affirmed by Fourth Circuit; and EU Advocate General Finds Member States Can Impose Measures to Protect News Content on Meta Platforms
- EU Publishes Code of Practice as Deadline for AI Act’s Provisions on General-Purpose AI Models Nears